Type 2 DiabetesNCT07606066
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
An observational study of Type 2 Diabetes, run by AstraZeneca at 76 sites in 7 countries.
Trial summary
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Procedure: assessment
- How many people
- 2,150 participants
- Where
- 76 sitesin 7 countries
- Study dates
- 6 May 2026to 31 Mar 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with Type 2 Diabetes
Who may be able to join
- Participants must be ≥ 18 years of age at the time of signing the ICF.
- Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
- Health Organization or local diagnostic standards, inadequately managed with:
- Lifestyle management alone, AND/OR
- A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
- Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
- Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.
Who cannot join
- Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
- Diagnosed with Type 1 diabetes mellitus.
- Known pregnancy at the time of visit or having the intention to become pregnant.
Trial locations and contacts
76 sites in 7 countries. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
76 sites in 7 countries
India19 sites, 19 recruiting
- Not yet recruiting
Research Site
Bangalore, Karnataka, 560092
- Not yet recruiting
Research Site
Belagavi, Karnataka, 590006
- Not yet recruiting
Research Site
Belagavi, Karnataka, 590010
- Not yet recruiting
Research Site
Calicut, Kerala, 673008
- Not yet recruiting
Research Site
Chennai, Tamil Nadu, 600086
- Not yet recruiting
Research Site
Coimbatore, Tamil Nadu, 641018
- Not yet recruiting
Research Site
Delhi, New Delhi, 110029
- Not yet recruiting
Research Site
Guntur, Andhra Pradesh, 522001
- Not yet recruiting
Research Site
Guwahati, Assam, 781032
- Not yet recruiting
Research Site
Indore, Madhya Pradesh, 452008
- Not yet recruiting
Research Site
Jaipur, Rajasthan, 302017
- Not yet recruiting
Research Site
Kochi, Kerala, 682041
- Not yet recruiting
Research Site
Kolkata, West Bengal, 700020
- Not yet recruiting
Research Site
Lucknow, Uttar Pradesh, 226030
- Not yet recruiting
Research Site
Mumbai, Maharashtra, 400012
- Not yet recruiting
Research Site
Nagpur, Maharashtra, 440010
- Not yet recruiting
Research Site
Pune, Maharashtra, 411013
- Not yet recruiting
Research Site
Pune, Maharashtra, 411021
- Not yet recruiting
Research Site
Thiruvananthapuram, Kerala, 695031
United States14 sites, 14 recruiting
- Recruiting
Research Site
Decatur, Georgia, 30030
- Not yet recruiting
Research Site
El Dorado, Kansas, 67042
- Recruiting
Research Site
Gaffney, South Carolina, 29340
- Not yet recruiting
Research Site
Jacksonville, Florida, 32256
- Recruiting
Research Site
Lake City, Florida, 32055
- Not yet recruiting
Research Site
Leesburg, Florida, 34748
- Recruiting
Research Site
Lincoln, California, 95648
- Recruiting
Research Site
Little Rock, Arkansas, 72205
- Not yet recruiting
Research Site
Maumee, Ohio, 43537
- Not yet recruiting
Research Site
Melrose Park, Illinois, 60160
- Recruiting
Research Site
Ocoee, Florida, 34761
- Not yet recruiting
Research Site
Peoria, Arizona, 85382
- Recruiting
Research Site
Potomac, Maryland, 20854
- Recruiting
Research Site
Renton, Washington, 98057
Brazil11 sites, 11 recruiting
- Not yet recruiting
Research Site
Barretos, 14784-400
- Not yet recruiting
Research Site
Brasília, 71625-009
- Not yet recruiting
Research Site
Campinas, São Paulo, 13060-904
- Recruiting
Research Site
Curitiba, Paraná, 80030-480
- Not yet recruiting
Research Site
Fortaleza, Ceará, 60430-350
- Not yet recruiting
Research Site
Natal, Rio Grande do Norte, 59020-035
- Not yet recruiting
Research Site
Porto Alegre, Rio Grande do Sul, 90630-165
- Not yet recruiting
Research Site
Rio de Janeiro, 22270-060
- Not yet recruiting
Research Site
São José dos Campos, São Paulo, 12243-280
- Not yet recruiting
Research Site
São Paulo, São Paulo, 01228-200
- Not yet recruiting
Research Site
São Paulo, São Paulo, 04012-180
Hungary10 sites, 10 recruiting
- Recruiting
Research Site
Budapest, HU, 1036
- Recruiting
Research Site
Budapest, HU, 1089
- Recruiting
Research Site
Budapest, 1024
- Recruiting
Research Site
Budapest, 1132
- Not yet recruiting
Research Site
Budapest, 1138
- Not yet recruiting
Research Site
Debrecen, HU, 4032
- Not yet recruiting
Research Site
Salgótarján, 3100
- Not yet recruiting
Research Site
Szeged, HU, 6725
- Not yet recruiting
Research Site
Szolnok, 5000
- Recruiting
Research Site
Zalaegerszeg, 8900
Poland9 sites, 9 recruiting
- Recruiting
Research Site
Bialystok, Podlaskie Voivodeship, 15-879
- Not yet recruiting
Research Site
Częstochowa, Silesian Voivodeship, 42-217
- Not yet recruiting
Research Site
Kielce, Świętokrzyskie Voivodeship, 25-355
- Not yet recruiting
Research Site
Krakow, Malopolska, 31-261
- Recruiting
Research Site
Lodz, Łódź Voivodeship, 90-338
- Not yet recruiting
Research Site
Lublin, Lublin Voivodeship, 20-718
- Recruiting
Research Site
Poznan, 60-354
- Not yet recruiting
Research Site
Radom, Masovian Voivodeship, 26-600
- Not yet recruiting
Research Site
Warsaw, 00-124
Turkey (Türkiye)8 sites, 8 recruiting
- Not yet recruiting
Research Site
Adana, 01060
- Not yet recruiting
Research Site
Adana, 01250
- Recruiting
Research Site
Ankara, Turkey, 6100
- Not yet recruiting
Research Site
Ankara, 06530
- Not yet recruiting
Research Site
Gaziantep, 27470
- Not yet recruiting
Research Site
Istanbul, 34265
- Not yet recruiting
Research Site
Istanbul, 34384
- Not yet recruiting
Research Site
Kayseri, 38039
Malaysia5 sites, 4 recruiting
- Withdrawn
Research Site
Batu Caves, Selangor, 68100
- Not yet recruiting
Research Site
Kuala Lumpur, Wilayah Persekutuan Kuala Lump, 59100
- Not yet recruiting
Research Site
Putrajaya, 62250
- Recruiting
Research Site
Seremban, Negeri Sembilan, 70300
- Not yet recruiting
Research Site
Seri Manjung, Perak, 32040
About this study
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
- Conditions
- Type 2 Diabetes
- Being tested
- Procedure: assessment
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Procedure: assessmentOther
The approximate volume of blood required is 2 mL
| Study group | Role | What they receive |
|---|---|---|
| Participants with Type 2 Diabetes | Participants with Type 2 Diabetes Receives: Other: Procedure: assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient demographics
Summary statistics
Measured: Visit 1 (Single day)
Medical and surgical history
Summary statistics
Measured: Visit 1 (Single day)
Concomitant medication
Summary statistics
Measured: Visit 1 (Single day)
HbA1c levels
Summary statistics
Measured: Visit 1 (Single day)
Secondary outcomes (1)
Referral to ongoing or future T2DM study.
Number of participants with high likelihood of meeting eligibility criteria in ongoing or future T2DM studies, for referral to those studies.
Measured: Visit 1 (Single day)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2026
- Study start6 May 2026
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 2,150 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07606066
- Sponsor's protocol ID
- D7261C00007
- Status last verified
- Mar 2026
- First submitted
- 30 Apr 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
- ClinicalTrials.gov ID
- NCT07606066
- Acronym / sponsor ID
- D7261C00007
- Conditions
- Type 2 Diabetes
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,150 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 6 May 2026 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Mar 2027 (estimated)
- First posted
- 26 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants with Type 2 Diabetes | – | Other: Procedure: assessmentParticipants with Type 2 Diabetes |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with Type 2 Diabetes
Key inclusion criteria (7 listed)
- Participants must be ≥ 18 years of age at the time of signing the ICF.
- Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
- Lifestyle management alone, AND/OR
- A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
Key exclusion criteria (3 listed)
- Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
- Diagnosed with Type 1 diabetes mellitus.
- Known pregnancy at the time of visit or having the intention to become pregnant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Procedure: assessmentThe approximate volume of blood required is 2 mL | Other | Participants with Type 2 Diabetes |
Primary outcome
Patient demographics
Time frame: Visit 1 (Single day)
Summary statistics
Medical and surgical history
Time frame: Visit 1 (Single day)
Summary statistics
Concomitant medication
Time frame: Visit 1 (Single day)
Summary statistics
HbA1c levels
Time frame: Visit 1 (Single day)
Summary statistics
1 secondary outcome
Referral to ongoing or future T2DM study.
Time frame: Visit 1 (Single day)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Related trials for Type 2 Diabetes
Not yet recruiting
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Active, not recruiting
Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management
Type 2 Diabetes Mellitus (T2DM)
Not yet recruiting
Care COMPASS Study
Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Enrolling by invitationObservational study
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
Type 2 Diabetes
RecruitingObservational study
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
Sarcopenia, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
76 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes, run by AstraZeneca at 76 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 76 sites in India, United States, Brazil, Hungary, Poland and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient demographics (time frame: Visit 1 (Single day)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.